`Date Filed: April 18, 2017
`
`Filed On Behalf Of: Novartis AG
`
`By: Nicholas N. Kallas
`
`NKallas@fchs.com
`
`ZortressAfinitorIPR@fchs.com
`
`(212) 218-2100
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`PAR PHARMACEUTICAL, INC.,
`BRECKENRIDGE PHARMACEUTICAL, INC. AND
`ROXANE LABORATORIES, INC.
`Petitioners,
`
`v.
`
`NOVARTIS AG,
`Patent Owner
`
`
`
`Case IPR2016-000841
`U.S. Patent 5,665,772
`
`
`
`PATENT OWNER’S UNOPPOSED
`NOTICE OF TRANSCRIPTION ERROR
`
`
`
`
`1 Breckenridge Pharmaceutical, Inc. was joined as a party to this proceeding via a
`Motion for Joinder in IPR2016-01023; Roxane Laboratories, Inc. was joined as a
`party via a Motion for Joinder in IPR2016-01102.
`
`
`
`Pursuant to the Board’s April 18, 2017 email authorizing Patent Owner
`
`Novartis AG (“Novartis”) to file an Unopposed Notice of Transcription Error in
`
`this proceeding, Novartis respectfully notifies the Board of the following
`
`transcription error in the Record of Oral Hearing (Paper No. 71), which was filed
`
`on March 15, 2017. As Novartis stated in its March 21, 2017 email to the Board,
`
`Petitioners Par Pharmaceutical, Inc., Roxane Laboratories, Inc., and Breckenridge
`
`Pharmaceutical, Inc. (“Petitioners”) have indicated that they do not oppose
`
`correction of the following error.
`
`At page 48, line 4 of the Record of Oral Hearing, the transcript incorrectly
`
`recorded a statement from Patent Owner’s counsel, Ms. Schwarz, regarding Lemke
`
`Table 16-1. Specifically, the transcript states “we think it is inappropriate when
`
`looking at Table 16-1 to look at the atoms that differ between Rapamycin and
`
`Everolimus. . . .” (Underscoring added.) Instead, Ms. Schwarz stated “we think it
`
`is appropriate when looking at Table 16-1 to look at the atoms that differ between
`
`Rapamycin and Everolimus. . . .” Evidence that Ms. Schwarz’s statement was
`
`mistranscribed is readily apparent from the discussion of Lemke Table 16-1 at
`
`page 42, line 16 to page 44, line 21, and page 46, line 2 to page 48, line 18 of the
`
`Record of Oral Hearing.
`
`
`
`1
`
`
`
`
`
`
`
`/Nicholas N. Kallas/
`Nicholas N. Kallas
`Registration No. 31,530
`Lead Counsel for Patent Owner
`FITZPATRICK, CELLA, HARPER
`& SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel. 212-218-2100
`
`
`
`Respectfully submitted,
`
`
`Dated: April 18, 2017
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2
`
`
`
`CERTIFICATE OF SERVICE
`
`I certify that a copy of the foregoing Patent Owner’s Unopposed
`
`Notice of Transcription Error was served on April 18, 2017, by causing it to
`
`be sent by email to counsel for Petitioners at the following email addresses:
`
`Daniel G. Brown (daniel.brown@lw.com)
`
`Robert Steinberg (bob.steinberg@lw.com)
`
`Brenda L. Danek (Brenda.danek@lw.com)
`
`
`
`Jonathan M. Strang (jonathan.strang@lw.com)
`
`Matthew L. Fedowitz (mfedowitz@merchantgould.com)
`
`B. Jefferson Boggs (jboggs@merchantgould.com)
`
`Daniel R. Evans (devans@merchantgould.com)
`
`Keith A. Zullow (kzullow@goodwinlaw.com)
`
`Marta Delsignore (mdelsignore@goodwinprocter.com)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/Nicholas N. Kallas/
`Nicholas N. Kallas
`Registration No. 31,530
`Lead Counsel for Patent Owner
`FITZPATRICK, CELLA,
`HARPER & SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel. 212-218-2100
`
`Dated: April 18, 2017
`
`
`
`
`
`
`
`
`
`
`
`3
`
`